In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 2: Local Treatments. Dr. Peter Carroll ...

Pedro Barata speaks with Tian Zhang about the PDIGREE phase III adaptive trial. This cooperative group study enrolled over 1,000 patients across 46 states over five years, representing a collaborative ...

Zachary Klaassen interviews Nicholas James about applying the ArteraAI prostate test to high-risk M0 prostate cancer patients from STAMPEDE. Dr. James explains how they analyzed M0 patients receiving ...

(UroToday.com) The 2025 AUA annual meeting featured a radiation therapy for localized prostate cancer session and a presentation by Dr. Anne Hong discussing the safety of stabilized hyaluronic acid as ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Maroun Bou Zerdan discussing the prognostic relevance of Aurora kinase A expression in prostate ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Rana McKay discussing the molecular and clinical characterization of KLK2 mRNA expression in ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. David Wise discussing a phase 1 study of gotistobart (BNT316/ONC-392) in combination with ...